Navigation Links
Discovery of therapeutic peptides affecting mitochondria
Date:11/9/2011

In 2010, after more than 10 years of basic research, Dr. Peter W. Schiller, a world-renowned peptide chemist and Director of the Chemical Biology and Peptide research unit at the Institut de recherches cliniques de Montral (IRCM), and his international collaborators were the listed inventors on two U.S. patents awarded to the institute and covering different uses of a unique class of peptide compounds initially synthesized in Dr. Schiller's laboratory at the IRCM.

A total of five U.S. patents have been awarded to the IRCM to date involving these new peptide compounds. Patent applications have also been filed in many other countries, including Canada, Europe, Japan, India, Australia, and China. The IRCM co-owns these patent families with Cornell University, located in New York state.

Stealth Peptides International Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies, has exclusively licensed commercial rights to the compounds and their various applications. Stealth plans to develop new treatments for metabolic, ophthalmologic, neurologic and cardio-renal diseases using these and other compounds.

Stealth's lead clinical candidate is BendaviaTM, a novel compound from this class of peptides that targets cell mitochondria to treat several acute and chronic diseases.

The first clinical program for Bendavia is for the treatment of ischemia reperfusion injury, a common complication of interventional procedures for acute myocardial infarction, a leading cause of death worldwide, as reported by the World Health Organization. An Investigational New Drug application for Bendavia was filed with the U.S. Food and Drug Administration and U.S. Phase I clinical trials began in May 2010. The initial U.S. Phase I clinical trial was designed to evaluate the clinical safety, tolerability and pharmacokinetics of Bendavia in healthy volunteers. In September 2010, Stealth's U.S. affiliate announced the completion of the U.S. Phase I study. The preliminary results from this clinical trial demonstrated that Bendavia appeared to be well tolerated at the doses evaluated, with no serious adverse events reported. A Phase II clinical trial has already begun in several countries.

In the "Top Ten"

Windhover, a company owned by Elsevier that plays a major role in the production of health industry analyses, chose Bendavia as one of the "Top 10" projects to watch for in 2011 in the development of therapies for cardiovascular and metabolic diseases.


'/>"/>
Contact: Julie Langelier
julie.langelier@ircm.qc.ca
514-987-5555
Institut de recherches cliniques de Montreal
Source:Eurekalert

Related biology news :

1. Chemical equator discovery will aid pollution mapping
2. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
3. Groundbreaking discovery may lead to stronger antibiotics
4. Discovery of natural compounds that could slow blood vessel growth
5. Nanoscopic screening process to speed drug discovery
6. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
7. New $11 million center to speed production of new compounds for drug discovery
8. Discovery of giant roaming deep sea protist provides new perspective on animal evolution
9. New discovery may enhance MRI scans, lead to portable MRI machines
10. Kidney function discovery sheds light on genetic complexity of disease
11. Discovery of new gene associated with diabetes risk suggests link with body clock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
Breaking Biology Technology: